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Abstract: Arsenic is toxic to many organ systems, the kidney being the most sensitive target organ.
We aimed to investigate whether, in kidney transplant recipients (KTRs), the nephrotoxic exposure to
arsenic could represent an overlooked hazard for graft survival. We performed a prospective cohort
study of 665 KTRs with a functional graft ≥1 year, recruited in a university setting (2008-2011), in The
Netherlands. Plasma arsenic was measured by ICP-MS, and dietary intake was comprehensively
assessed using a validated 177-item food-frequency questionnaire. The endpoint graft failure was
defined as restart of dialysis or re-transplantation. Median arsenic concentration was 1.26 (IQR,
1.04-2.04) µg/L. In backwards linear regression analyses we found that fish consumption (std β = 0.26;
p < 0.001) was the major independent determinant of plasma arsenic. During 5 years of follow-up,
72 KTRs developed graft failure. In Cox proportional-hazards regression analyses, we found that
arsenic was associated with increased risk of graft failure (HR 1.80; 95% CI 1.28–2.53; p = 0.001).
This association remained materially unaltered after adjustment for donor and recipient characteristics,
immunosuppressive therapy, eGFR, primary renal disease, and proteinuria. In conclusion, in KTRs,
plasma arsenic is independently associated with increased risk of late graft failure.
Keywords: arsenic; diet; fish consumption; oxidative stress; kidney transplantation; graft failure
J. Clin. Med. 2020, 9, 417; doi:10.3390/jcm9020417 www.mdpi.com/journal/jcm
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1. Introduction
Arsenic is toxic to many organ systems, the kidney being the most sensitive target organ [1,2]. Free
radical mediated-oxidative damage is the cornerstone of arsenic-induced pathology [3]. Arsenic induces
morphological alterations of mitochondria that lead to uncontrolled formation of free radicals [4],
whilst it inhibits the production of glutathione that protects cells from oxidative damage, ultimately
yielding irreversible cell damage [5,6]. The kidney being a major player in removal of arsenic from
the system, it is also very much exposed to arsenic and therefore susceptible to arsenic-induced
toxicity [7–10].
A large variety of arsenic compounds are known, divided into the elemental metal, inorganic,
and organic compounds with a large variety of toxicity [1,2,11,12]. While an extraordinary cause for
arsenic intake has been described as hydroarsenicism—contamination of drinking water with arsenic
in the US, Chile, and Taiwan—arsenic in food is an increasingly recognized pathway of environmental
exposure. Thus, upon background regional differences, arsenic exposure substantially derives from
rice consumption, as well as vegetables, fruits, and herbal tea [13–19]. Of note, however, seafood is
thought to be a major route for arsenic intake, followed by alcohol consumption, with the latter mainly
due to contaminated wine, therewith representing an evident public health threat [20,21].
Basic and clinical evidence has linked arsenic exposure to nephrotoxicity, tubular necrosis, diffuse
interstitial fibrosis, decline of kidney function, incident chronic kidney disease, and progress of
native chronic kidney disease, among several other conditions such as hypercalciuria, albuminuria,
and nephrocalcinosis [22–29]. Kidney transplant recipients (KTRs) are particularly vulnerability to the
harmful effects of nephrotoxic agents. However, no study has been devoted to evaluating whether
arsenic may be an otherwise overlooked modifiable risk factor in the post-kidney transplantation
setting. The current study, therefore, aimed to identify independent environmental and system
determinants of plasma arsenic levels and to evaluate the potential association of plasma arsenic levels
with long-term risk of graft failure in a large cohort of well-characterized KTRs.
2. Methods
2.1. Design and Study Population
In this prospective cohort study, outpatient adult KTRs with a functioning graft ≥1 year, no
alcohol or drug addiction, and without known systemic illnesses (i.e., malignancies, opportunistic
infections) were invited to participate. The recruitment of patients took place at the University Medical
Center Groningen between November 2008 and March 2011. In total, 817 KTRs were invited for the
study, of whom 707 (87%) provided written informed consent to participate. All patients with missing
plasma arsenic levels were excluded, resulting in 665 KTRs eligible for statistical analyses. Multiple
imputations (n = 5) were used to account for missingness of data among variables other than data
on circulating arsenic. The present study was approved by the Institutional Review Board (METc
2008/186) and was conducted in accordance with the Declaration of Helsinki.
The primary outcome of this study was death-censored graft failure, defined as end-stage kidney
disease requiring dialysis or re-transplantation. The continuous surveillance system of the outpatient
clinic of our university hospital, in which patients visit the outpatient clinic with declining frequency
in accordance with the American Transplantation Society Guidelines, ensured updated information on
patient status [30]. General practitioners or referring nephrologists were contacted in case the status
of a patient was unknown. Endpoints were recorded until September 2015. No patients were lost
to follow-up.
All KTRs were transplanted at the University Medical Center Groningen following the
establishment of standard antihypertensive and immunosuppressive therapies. Relevant characteristics
including recipient age, gender, cardiovascular history, and transplant-related information were
extracted from patient records. Dietary intake, clinical parameters, and laboratory measurements were
extensively assessed at baseline.
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2.2. Assessment of Dietary Intake
Dietary intake was assessed using a validated semi-quantitative food frequency questionnaire
(FFQ) developed and updated at Wageningen University [31]. The questionnaire consisted of 177 food
items to record intake during the last month, taking seasonal variations into account. For each item,
the frequency was expressed in times per day, week, or month. The number of servings was recorded
in natural units (e.g., slice of bread or apple) or household measures (e.g., cup or spoon). The FFQ was
self-administered and then checked by a trained researcher on the day of visit to the outpatient clinic.
Inconsistent answers were verified with the patients. The results of the FFQ were converted into total
energy and nutrient intake per day by using the Dutch Food Composition Table of 2006 [32].
2.3. Clinical Parameters and Definitions
All measurements were performed during a morning visit to the outpatient clinic. Blood pressure
was determined with a semi-automatic device (Dinamap 1846, Critikon, Tampa, FL, USA), measuring
every minute for 15 min. The last three measurements were averaged, following a strict protocol as
described previously [33]. Body mass index (BMI) was calculated as weight in kilograms divided by
height in meters squared (kg/m2), and body surface area (BSA) was estimated in meters squared (m2)
by using the universally adopted formula of DuBois and DuBois [34]. Diabetes was defined as use of
antidiabetic medication, fasting plasma glucose ≥ 7.0 mmol/L, and/or HbA1C higher than 6.5% [35].
Kidney function was assessed by means of estimated glomerular filtration rate (eGFR) according to the
Chronic Kidney Disease Epidemiology Collaboration equation [36].
2.4. Laboratory Methods and Arsenic Measurement
Blood was drawn after a fasting period of 8–12 h, which included no medication intake. Serum
high-sensitivity C-reactive protein (hs-CRP), HbA1C, triglycerides, low-density lipoprotein (LDL)
cholesterol, high-density lipoprotein (HDL) cholesterol, and total cholesterol were measured using
routine laboratory methods. Serum creatinine was determined using a modified version of the Jaffé
method (MEGA AU 510, Merck Diagnostica, Darmstadt, Germany). Serum cystatin C was determined
using Gentian Cystatin C Immunoassay (Gentian AS, Moss, Norway) on a modular analyzer (Roche
Diagnostics, Mannheim, Germany). Class I and class II human leukocyte antigens (HLA) antibodies
were assessed by ELISA (LATM20×5, One Lambda, Canoga Park, CA, USA) as described elsewhere [37].
According to a strict protocol, all participants were instructed to collect a 24 h urine sample the day
before to their visit to the outpatient clinic. Total urinary protein concentration was determined using
the Biuret reaction (MEGA AU 150, Merck Diagnostica, Darmstadt, Germany).
Arsenic plasma concentrations were assessed from EDTA plasma samples that were stored
frozen at −80 ◦C. Arsenic plasma concentrations were determined using inductively coupled plasma
mass spectrometry (ICP-MS, Varian 820-MS; Varian, Palo Alto, CA, USA) with a modified method
for the measurement of low concentrations of heavy metals in plasma using a standard addition
method. Standards were made by addition to blanc plasma known amounts of arsenic to obtain added
concentrations of 0.500, 1.00, 2.00, 3.00, 4.00, and 5.00 µg/L. Control samples were made by spiking
blanc plasma with known amounts of arsenic to obtain added concentrations of, respectively, 0.75 (low),
2.5 (medium), and 4.5 µg/L (high). Sample preparation consisted of diluting 100 µL sample with 1.0 mL
dilution reagent. The dilution reagent contained 0.005% Triton X100, 0.005% EDTA, and 0.1 mg/L
Yttrium as internal standard. Characteristics of this method are summarized in Table 1.
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Table 1. Bias and precision of arsenic measurements.
Cadmium Concentration n µg/L Bias (%)
Inter-Assay Coefficient
SD (µg/L) CV (%)
Low 36 0.75 −13 0.26 40
Medium 36 2.5 −9.2 0.38 17
High 37 4.5 −6 0.48 11
n, number of control samples; SD, standard differentiation; CV, coefficient of variation.
2.5. Follow-Up of Plasma Arsenic Levels in a Sample Population of the TransplantLines Cohort and
Biobank Study
Additionally, to investigate plasma arsenic levels over time, we requested follow-up plasma
samples (3 months, 6 months, 1 year, and 2 years post-kidney transplantation) from 46 consecutive
KTRs enrolled between February 2016 and May 2017 in the ongoing TransplantLines Prospective
Cohort and Biobank Study [38]. Arsenic plasma concentrations were determined using inductively
coupled plasma mass spectrometry (ICP-MS, Varian 820-MS; Varian, Palo Alto, CA, USA) with a
modified method for the measurement of low concentrations of heavy metals in plasma using a
standard addition method, as described hereby in the preceding section.
2.6. Statistical Analyses
Data analyses were performed using SPSS version 23.0 software (SPSS, Inc., Chicago, IL, USA) and
R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were
summarized using mean (SD) for normally distributed data, whereas skewed distributed variables
are given as median (IQR). Categorical variables were summarized as numbers (percentage). In all
analyses, a two-sided p < 0.05 was considered significant. Linear regression analyses were performed
to evaluate the association of baseline characteristics with arsenic concentrations, adjusted for (i) age
and sex, and additionally (ii) eGFR. The assumption of homoscedasticity and normality of residual
variance were verified, and a natural log-transformation was applied when appropriate. Std. β
coefficients represent the difference (in SD) in arsenic per 1-SD increment in continuous characteristics
or for categorical characteristics the difference (in SD) in arsenic compared to the implied reference
group. In order to study, in an integrated manner, which baseline characteristics were independently
associated with and were determinants of plasma arsenic, we performed forward selection of baseline
characteristics according to preceding multivariable linear regression analyses (p for inclusion < 0.2),
followed by stepwise backwards multivariable linear regression analyses (p for exclusion 0.05). Finally,
we also performed a stepwise backwards multivariable linear regression with exclusion of eGFR in the
initial model in order to isolate environmental determinants of plasma arsenic levels.
The prospective association of plasma arsenic with risk of graft failure during follow-up was
examined incorporating time to event and accounting for death-censoring, by means of univariable
and multivariable Cox proportional-hazards regression analyses with time-dependent covariates to
calculate hazard ratios (HR) and 95% confidence intervals (CI). Schoenfeld residuals were calculated
to assess whether proportionality assumptions were satisfied. Associations are shown with plasma
arsenic as a continuous variable and according to tertiles of the plasma arsenic distribution. Following
univariable analyses (model 1), we first performed multivariable adjustment for the most important
environmental determinants of arsenic levels according to the results of our backwards linear regression
analyses (model 2). To avoid overfitting, further models were performed with additive adjustments to
model 2, defined as the primary multivariable model [39]. Thus, we performed additional adjustments
for intake of fruits, vegetables, potato, rice, bread, and total energy intake (model 3); transplant
characteristics (donor and recipient age, donor type, HLA mismatches, circulating anti-HLA class
I antibodies, circulating anti-HLA class II antibodies, transplant vintage, and immunosuppressive
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therapy; model 4); risk factors of graft failure (eGFR, hs-CRP, systolic blood pressure, total cholesterol,
and triglycerides concentration; model 5); and primary renal disease and proteinuria in model 6.
The intra-individual coefficient of variation (CV) for plasma arsenic levels in KTRs of the
TransplantLines Cohort and Biobank Study was calculated using the formula CV = (SD/mean) × 100,
in which SD is the standard deviation and mean is the mean value for plasma arsenic concentrations as
measured in follow-up samples taken at 3 months, 6 months, 1 year, and 2 years post transplantation.
Next, box plots were used to illustrate medians (interquartile range) of plasma arsenic levels during
follow-up visits. Finally, significance of potential change during follow-up visits was tested using the
Kruskal Wallis test.
3. Results
3.1. Baseline Characteristics and Cross-Sectional Analyses
Mean (SD) age of the 665 KTRs was 53 (13) years, of whom 383 (58%) were male. Median (IQR)
plasma arsenic concentration was 1.26 (1.04–−2.04) µg/L. The baseline characteristics of the study
participants along with the results of age- and sex- as well as eGFR-adjusted linear regression analyses
are shown in Table 2. In stepwise backward multivariable linear regression analysis, fish consumption
(β = 0.26; p < 0.001), eGFR (β = −0.11; p = 0.02), and proteinuria (std β = 0.18; p < 0.001) were identified
as independent determinants of plasma arsenic concentrations (Table 2). If analyses were performed
with eGFR excluded from the initial model, fish consumption (β = 0.27; p < 0.001) was identified as the
only independent determinant of arsenic (Table 2).
3.2. Prospective Analyses
During a follow-up of 5 years, 72 (11%) patients developed graft failure. Chronic allograft
dysfunction was the major cause of graft failure accountable for 50 (69%) of all graft failures. Other
causes for graft failure included return of primary kidney disease (11%), infection (4%), acute rejection
(4%), BK nephropathy (4%), vascular complications (3%), and others (4%). From low to high tertiles of
the plasma arsenic distribution, 18, 25, and 29 patients developed graft failure, respectively. Prospective
analyses of the association of plasma arsenic with death-censored graft failure are shown in Table 3.
Multivariable-adjusted Cox proportional hazards models showed that plasma arsenic was directly
associated with graft failure (HR 1.80; 95% CI 1.28–2.53, p = 0.001), independent of major environmental
determinants of arsenic concentration, i.e., alcohol and fish consumption. In analyses with further
adjustment for potential confounders, the association remained materially unchanged (Table 3). We
did not find signs of a non-linear association between plasma arsenic levels and risk of death-censored
graft failure (Supplementary Materials Table S1). Figure 1 illustrates the association between plasma
arsenic concentration and risk of death-censored graft failure using Cox regression analyses with mean
concentration of plasma arsenic as reference, adjusted for age, sex, fish intake and alcohol consumption,
and in relation to the histogram of plasma arsenic distribution.
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Table 2. Baseline characteristics of 665 kidney transplant recipients (KTRs) and their association with plasma arsenic.










Std. β Std. β Std. β Std. β
Plasma arsenic, µg/L, median (IQR) 1.26 (1.04–2.04) − − − −
Demographics and body composition
Age, years, mean (SD) 53 (13) − −
Sex (male), n (%) 383 (58) − −
Diabetes mellitus, n (%) 160 (24) −0.07 * −0.07 * ~ ~
Body surface area, m2, mean (SD) 1.94 (0.22) −0.02 −0.05
Body mass index, kg/m2, median (IQR) 26.0 (23.3–29.4) −0.003 −0.02
Waist circumference, cm, mean (SD) 99 (14) 0.003 −0.02
Cardiovascular history and lifestyle
History of cardiovascular disease, n (%) 325 (49) −0.01 −0.01
Heart rate, beats per minute, mean (SD) 69 (12) 0.01 0.02
Systolic blood pressure, mmHg, mean (SD) 136 (17) −0.04 −0.06 * ~ ~
Use of antihypertensives, n (%) 586 (88) 0.001 −0.04
Current or former smoker, n (%) 382 (57) 0.04 0.03
Alcohol consumption > 10 g/d, n (%) 169 (25) 0.14 *** 0.14 *** ~
Dietary intake
Bread, g/day, mean (SD) 133 (59) −0.09 ** −0.08 * ~ ~
Vegetables, g/day, median (IQR) 90 (50–118) −0.03 −0.03
Fruit, g/day, median (IQR) 123 (61–232) −0.04 −0.04 ~ ~
Potato, g/day, median (IQR) 119 (72–161) −0.11 *** −0.11 ** ~ ~
Rice, g/day, median (IQR) 15 (4–32) 0.07 * 0.06 * ~ ~
Fish, g/day, median (IQR) 11 (4–21) 0.32 *** 0.31 *** 0.26 *** 0.27 ***
Coffee, mg/day, median (IQR) 500 (250–625) −0.001 0.01
Tea, mg/day, median (IQR) 250 (54–375) 0.03 0.01 * ~ ~
Laboratory measurements
Albumin, g/L, mean (SD) 43 (3) −0.05 −0.03
Calcium, mmol/L, mean (SD) 2.40 (0.15) −0.06 * −0.04
Phosphate, mmol/L, mean (SD) 0.97 (0.21) 0.09 ** 0.03
eGFR, mL/min/1.73 m2, mean (SD) 53 (20) −0.18 *** − −0.11 ** −
Proteinuria, n (%) 150 (23) 0.12 *** 0.09 ** 0.18 ***
Alkaline phosphatase, U/L, median (IQR) 67 (54–84) 0.02 0.02
ASAT, U/L, median (IQR) 22 (18–27) 0.06 * 0.07 * ~ ~
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Table 2. Cont.










Std. β Std. β Std. β Std. β
ALAT, U/L, median (IQR) 19 (14–25) 0.01 0.04
Gamma-GT, U/L, median (IQR) 26 (18–41) 0.05 * 0.05
Lipids
Total cholesterol, mmol/L, mean (SD) 5.1 (1.1) 0.03 0.02
HDL cholesterol, mmol/L, median (IQR) 1.3 (1.1–1.6) 0.04 0.08 * ~ ~
LDL cholesterol, mmol/L, mean (SD) 3.0 (0.9) 0.02 0.01
Triglycerides, mmol/L, median (IQR) 1.7 (1.2–2.3) −0.01 −0.04
Inflammation and oxidative stress
Leukocyte count, per 109/L, mean (SD) 8.1 (2.6) 0.01 0.01
hs-CRP, mg/L, median (IQR) 1.6 (0.7–4.5) −0.01 −0.02
Malondialdehyde, µmol/L, median (IQR) 2.5 (1.9–3.7) −0.02 −0.01
Primary kidney disease and kidney transplantation
Primary kidney disease
Glomerulosclerosis, n (%) 190 (29) 0.02 0.01
Glomerulonephritis, n (%) 51 (8) 0.01 −0.01
Tubulointerstitial nephritis, n (%) 76 (11) 0.05 0.06
Polycystic kidney disease, n (%) 136 (21) −0.09 −0.07
Kidney hypo/dysplasia, n (%) 29 (4) 0.02 0.02
Renovascular disease, n (%) 38 (6) −0.05 −0.04
Diabetes, n (%) 32 (5) 0.04 0.04
Other/miscellaneous, n (%) 113 (17) 0.02 0.02
Donor type, living n (%) 229 (34) −0.05 −0.04
Donor age, years, median (IQR) 46 (31–54) −0.01 −0.06 * ~ ~
Transplant vintage, years, median (IQR) 5.5 (2.0–11.9) −0.03 −0.01
Immunosuppressive therapy
Prednisolone dose, grams, median (IQR) 10.0 (7.5–10.0) 0.01 0.02
Use of calcineurin inhibitor, n (%) 381 (57) 0.05 0.003
Use of proliferation inhibitor, n (%) 553 (83) −0.001 0.02
Acute rejection treatment, n (%) 176 (26) 0.04 0.03
* p < 0.2; ** p < 0.05; *** p < 0.01. † Linear regression analysis; adjusted for age, sex, ‡ and eGFR. Std β coefficients represent the difference (in SD) in arsenic per SD increment in continuous
characteristics or for categorical characteristics the difference (in SD) in arsenic compared to the implied reference group. For inclusion and exclusion in stepwise backwards linear
regression analyses p values were set at 0.2 and 0.05, respectively. § eGFR was removed from the initial model. ~ Excluded from the final models. ALAT, alanine aminotransferase; ASAT,
aspartate aminotransferase; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HLA, human leukocyte antigens; hs-CRP, high-sensitivity C-reactive protein; LDL,
low-density lipoprotein.
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Table 3. Prospective analyses of the association of plasma arsenic with death-censored graft failure in
665 kidney transplant recipients.
Plasma Arsenic
Tertile 1 Tertile 2 Tertile 3 Continuous (ln)
Ref. HR (95% CI) HR (95% CI) HR (95% CI) p
nevents 18 25 29 72
Model 1 1.00 1.41 (0.77–2.59) 1.69 (0.94–3.04) 1.47 (1.08–2.01) 0.02
Model 2 1.00 1.58 (0.86–2.92) 2.12 (1.14–3.95) 1.80 (1.28–2.53) 0.001
Model 3 1.00 1.55 (0.84–2.87) 2.05 (1.10–3.82) 1.74 (1.24–2.45) 0.001
Model 4 1.00 1.40 (0.75–2.61) 2.00 (1.06–3.77) 1.90 (1.32–2.73) 0.001
Model 5 1.00 1.32 (0.71–2.45) 1.76 (0.93–3.32) 1.56 (1.10–2.23) 0.01
Model 6 1.00 1.29 (0.70–2.40) 1.84 (0.99–3.42) 1.53 (1.09–2.14) 0.01
Cox proportional-hazards regression analyses were performed to assess the association of plasma arsenic with risk
of death-censored graft failure (number of events = 72). Associations are shown with plasma arsenic concentration
as a continuous variable and according to tertiles of the plasma arsenic distribution (tertile 1: ≤1.1 µg/L; tertile 2:
1.1-1.67 µg/L; tertile 3: ≥1.67 µg/L). Model 1 is univariable. Multivariable model 2 was adjusted for fish intake and
alcohol consumption. Subsequently, additive adjustment was performed for intake of fruits, vegetables, potato, rice,
bread, and total energy intake (model 3); donor and recipient age, donor type, human leukocyte antigen mismatches
(HLA), circulating anti-HLA class I antibodies, circulating anti-HLA class II antibodies, transplant vintage, and
immunosuppressive therapy (model 4); eGFR, high-sensitivity C-reactive protein, systolic blood pressure, total
cholesterol, and triglyceride concentration (model 5); primary kidney disease and proteinuria (model 6).
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3.3. Follow-up of Plasma Arsenic Levels in a Sample Population of the TransplantLines Cohort and
Biobank Study
In Supplementary Materials Figure S1 we show box plots with medians (IQR) of plasma arsenic
concentration of 46 KTRs (mean age 52 ± 14 years-old, eGFR 43 ± 28 mL/min/1.72 m2) from the
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TransplantLines Prospective Cohort and Biobank Study, at different follow-up visits post-kidney
transplantation. Median (interquartile range) plasma arsenic concentrations were 1.61 (1.51–1.99),
1.64 (1.52–2.05), 1.64 (1.43–1.94), and 1.59 (1.46–2.26) µg/L at 3 months, 6 months, 1 year, and 2 years
post-kidney transplantation, respectively. Median (interquartile range) intra-individual coefficient of
variation was 12.2% (6.7–28.7%), and we did not find signs of a significant change in plasma arsenic
levels over time (p = 0.64).
4. Discussion
In these analyses of 665 well-characterized individuals from a Dutch cohort of KTRs, we identified
fish consumption as the major environmental determinant of plasma arsenic levels. Prospective
analyses showed that higher plasma arsenic levels are associated with increased long-term risk of
graft failure, independent of donor and recipient characteristics, immunosuppressive therapy, eGFR,
and proteinuria. These data pose arsenic as a potentially modifiable risk factor for late graft failure
in KTRs, emphasizing the need for specific recommendations regarding arsenic exposure, as well as
patient monitoring and management of arsenic-induced kidney injury, particularly in populations
highly susceptible to nephrotoxic agents such as KTRs.
Being the major organ involved in arsenic clearance, the kidney is highly susceptible and the most
sensitive target organ to arsenic exposure [1,2,9,10]. Arsenic-induced oxidative stress has been suggested
to be the cornerstone of pathological mechanisms leading to kidney injury and development of chronic
kidney disease [3,40]. On the one hand, decreased antioxidant capacity has been shown in individuals
exposed to arsenic [41], wherein depletion of glutathione has been consistently described [5,42,43].
Of note, by protecting cells from oxidative damage, inhibition of glutathione production and subsequent
glutathione depletion ultimately reverberates into increased vulnerability of cells to arsenic damage.
On the other hand, it has been shown that arsenic induces morphological alterations of mitochondrial
integrity that lead to uncontrolled free radical formation [4], which further feeds the circle of oxidative
challenge and tissue injury. Indeed, basic and clinical evidence has linked arsenic exposure to
nephrotoxicity, tubular necrosis, diffuse interstitial fibrosis, decline of kidney function, incident chronic
kidney disease, and progress of native chronic kidney disease, amongst other conditions such as
hypercalciuria, albuminuria, and nephrocalcinosis [22–29]. Subsequently, diminished kidney clearance
of arsenic and enhanced production of reactive oxygen species longitudinally contribute to perpetuate
tissue insult and progression of chronic kidney disease [22,23]. Previous studies have also shown an
association between arsenic and hypertension and type 2 diabetes mellitus, both suggesting additional
mechanisms for secondary kidney damage [44,45]. Ecological studies from the United States, Chile,
and Taiwan have shown that arsenic exposure is associated with increased mortality from kidney
disease [13–15,22,26,28,46–49]. KTRs are particularly vulnerable to harmful effects of nephrotoxic
agents. End-stage kidney disease and maintenance immunosuppressive therapy are constant sources
of oxidative challenge for the graft tissue, which shortens the capacity of oxidative stress defenses
against additional environmental hazards. To our knowledge, the current study is the first to provide
evidence of an independent prospective association between circulating arsenic levels and risk of late
kidney graft failure.
Further supportive evidence for the key role of oxidative stress in arsenic-induced pathogenic
mechanisms—and suggestive of potential management alternatives—was provided by the observation
that co-administration of ascorbic acid and α-tocopherol to arsenic-exposed rats led to a reduction in
the levels of lipid peroxidation, protein carbonyls, and hydrogen peroxide along with increased levels
of reduced glutathione, ascorbic acid, and α-tocopherol. Investigation aimed to evaluating whether
ascorbic acid and α-tocopherol supplementation may improve arsenic-induced altered microsomal
functions in the kidney is warranted [50].
An increasing body of evidence supports that the kidney is a primary site of arsenic uptake and
accumulation. Recently, X-ray fluorescence spectrometry allowed detection of arsenic accumulation,
specifically at level of the kidney cortex [51]. X-ray fluorescence spectrometry may provide
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comprehensive information of bioaccumulation for biomedical and toxicological research by allowing
direct measurement of the distribution of arsenic at tissue, cellular, and subcellular level. Next, X-ray
absorption spectroscopy has been shown to allow in vivo assessment of whole-body distribution, which
is key information for the development of chelation therapies [52]. Future studies using these analytical
methods may provide essential research data to understand the sequence of specific mechanisms of
nephrotoxicity and deepen the understanding of the association between long-term arsenic exposure
and kidney damage [51].
The current study is etiological in nature, which needs to be separated from prediction research [53].
Whereas the latter is a distinct field of epidemiologic research aimed at predicting the risk of an outcome
according to a model of statistically significant predictors, which not necessarily represents causal
associations, etiological studies aim to understand a certain pathway of a disease in an attempt to
prevent its onset or progression [53]. Taken together, our findings and the aforementioned studies
may support an etiological role of arsenic in pathways of disease that contribute to increased risk of
death-censored graft failure.
Data on the average diet-derived arsenic exposure in The Netherlands are scarce. One study
reported an estimated median (range) exposure of 37.8 (20.6–70.1) µg/day [54]. This was corroborated
by a more recent study of Hoogenboom et al. stating that the average diet-derived arsenic exposure is
<50 µg/day. In agreement with our findings, higher intake of arsenic most frequently originates from
higher fish consumption [55]. A monitoring program from the Dutch Agriculture Advisory Committee
(LAC), conducted in the 1980s, demonstrated that levels of arsenic in fish landed in The Netherlands
varied between 0.8 and 6.8 mg/kg wet weight, showing a slight decreasing trend over time. Likewise,
the arsenic levels in shrimps decreased from 4.3 to 1.3 mg/kg wet weight during that period (LAC
program, 1991, in reference [41]). However, more recent data regarding arsenic-contaminated fish
landed in The Netherlands are lacking and needed to evaluate strategies aiming to reduce the dietary
consumption of arsenic by the population. Next, although in The Netherlands, naturally occurring
arsenic concentrations in drinking water are usually below the concentrations required by the European
drinking water standard (<10 µg/L in all countries, except Denmark, where it is <5 µg/L), health risks
cannot be excluded at this level, and it has been recommended to optimize water supply to arsenic
levels <1 µg/L [56,57].
The current study was performed in a large cohort of extensively phenotyped KTRs, allowing
us to control our main findings for several potential confounders, including donor and recipient
characteristics, immunosuppressive therapy, proteinuria, and eGFR. Moreover, patients were monitored
for an extensive period and patient status was updated without losses to follow-up, allowing the
study of the long-term association of arsenic with graft failure. Despite considerable improvement of
short-term graft survival during last decades, improvement of long-term outcomes continues to lag
behind, emphasizing that future advances in the field of kidney transplantation are expected from the
amelioration of long-term graft attrition [58]. Systematic description of modifiable risk factors is key to
promote preventive strategies particularly addressed for this population of solid organ patients.
Our study derived from a single university center from the northern part of The Netherlands, which
calls for prudence to extrapolate our results to different populations regarding potential environmental
arsenic contamination and exposure. Additionally, the observational design of the current study
does not allow hard conclusions on causality, nor could the potentiality of reversed causation or
residual confounding be eliminated, despite the substantial number of potential confounders for
which we adjusted. Furthermore, the technique used in the current study does not allow different
species of arsenic to be distinguished, while arsenic species have major varieties in toxicity [1–4,11,12].
Elemental arsenic is nontoxic as the metal is insoluble in bodily fluids, and inorganic species of
arsenic, e.g., arsenite and arsenate, are especially toxic to humans. Organic species vary in toxicity; the
most common species, monomethylarsonic acid and dimethylarsinic acid, are less toxic compared to
inorganic species, and arsenobetaine and arsenosugars have a very low toxicity [1,5,9,11,59–61]. Further
studies utilizing techniques with the ability to distinguish between the different species of arsenic,
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e.g., high-performance liquid chromatography–inductively coupled plasma-mass spectrometry, could
provide more information on the impact of the different species on graft failure in KTRs. A further
limitation is that adjustment for immunological factors as potential confounders of the association
was limited to adjustment for HLA matching, circulating anti-HLA class I antibodies, and circulating
anti-HLA class II antibodies, since we had no data on donor-specific anti-HLA antibodies and biopsy
findings. Finally, it should be acknowledged that graft failure can be the consequence of multiple,
heterogenous causes. Unfortunately, in our study the numbers of cause-specific cases of death-censored
graft failure was too small to allow for meaningful separate analyses [62]. Larger studies are warranted
to comprehensively evaluate the association of plasma arsenic with different causes of death-censored
graft failure. It should be noticed, however, that this study is the first to indicate a prospective
association of arsenic with the hard endpoint graft failure, thus holding a plea for future studies which
to only investigate arsenic plasma concentrations, but also take into account concentrations of arsenic
in drinking water, and not only in KTRs to investigate associations with death-censored graft failure,
but also in other populations, such as patients with diabetes and the general population.
5. Conclusions
In conclusion, the current study shows for the first time that circulating arsenic levels are
independently associated with higher risk of late kidney graft failure, emphasizing the need for
specific recommendations regarding arsenic exposure, as well as patient monitoring and management
of chronic arsenic-induced kidney damage. Our findings point towards arsenic as an otherwise
overlooked modifiable risk factor for adverse long-term kidney outcomes, especially in populations of
vulnerability to oxidative stress challenge, e.g., KTRs. Further studies are warranted to confirm our
results and investigate the longitudinal association between arsenic exposure and graft failure in KTRs
from populations with different dietary and environmental exposure.
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